Based on the key measurements obtained from Nautilus Biotechnology's financial statements, Nautilus Biotechnology is not in a good financial situation at this time. It has a very high odds of going through financial crisis in January. At this time, Nautilus Biotechnology's Net Working Capital is comparatively stable compared to the past year. Key indicators impacting Nautilus Biotechnology's financial strength include:
The essential information of the day-to-day investment outlook for Nautilus Biotechnology includes many different criteria found on its balance sheet. An individual investor should monitor Nautilus Biotechnology's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Nautilus Biotechnology.
Please note, the imprecision that can be found in Nautilus Biotechnology's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Nautilus Biotechnology. Check Nautilus Biotechnology's Beneish M Score to see the likelihood of Nautilus Biotechnology's management manipulating its earnings.
Nautilus Biotechnology Stock Summary
Nautilus Biotechnology competes with C4 Therapeutics, Kymera Therapeutics, Foghorn Therapeutics, Revolution Medicines, and Century Therapeutics. Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company was founded in 2016 and is headquartered in Seattle, Washington. Nautilus Biotechnology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 124 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Nautilus Biotechnology's current stock value. Our valuation model uses many indicators to compare Nautilus Biotechnology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Nautilus Biotechnology competition to find correlations between indicators driving Nautilus Biotechnology's intrinsic value. More Info.
Nautilus Biotechnology is regarded fifth in return on equity category among its peers. It is regarded fourth in return on asset category among its peers . At this time, Nautilus Biotechnology's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Nautilus Biotechnology by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Nautilus Biotechnology Systematic Risk
Nautilus Biotechnology's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Nautilus Biotechnology volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Nautilus Biotechnology correlated with the market. If Beta is less than 0 Nautilus Biotechnology generally moves in the opposite direction as compared to the market. If Nautilus Biotechnology Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Nautilus Biotechnology is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Nautilus Biotechnology is generally in the same direction as the market. If Beta > 1 Nautilus Biotechnology moves generally in the same direction as, but more than the movement of the benchmark.
Nautilus Biotechnology Thematic Clasifications
Nautilus Biotechnology is part of Measuring and Control Equipment investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Measuring and Control Equipment industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Measuring and Control Equipment industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in Nautilus Biotechnology Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Nautilus Biotechnology's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Nautilus Biotechnology growth as a starting point in their analysis.
Price Earnings To Growth Ratio
0.26
At this time, Nautilus Biotechnology's Price Earnings To Growth Ratio is comparatively stable compared to the past year.
Nautilus Biotechnology December 2, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Nautilus Biotechnology help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Nautilus Biotechnology. We use our internally-developed statistical techniques to arrive at the intrinsic value of Nautilus Biotechnology based on widely used predictive technical indicators. In general, we focus on analyzing Nautilus Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Nautilus Biotechnology's daily price indicators and compare them against related drivers.
When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.